Former Puma Biotech executive gets U.S. prison term for insider trading
Robert Gadimian Charged with Insider Trading
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Puma Biotech (NYSE: PBYI) Stock Skyrockets 300% on Breast Cancer Breakthrough
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) US$24m market value fall may be overlooked by institutional investors after a year of 1.6% returns - Simply Wall St News
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
What Happened To Puma Biotechnology?
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology (NASDAQ:PBYI) Stock Price News
Puma Biotechnology Stock (NASDAQ:PBYI), Quotes and News Summary - Benzinga
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
Puma Biotechnology wins extension for U.S. patent related to breast cancer therapy | Seeking Alpha
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (NASDAQ:PBYI) Stock Price News
Puma Biotechnology
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
